Dan G. Duda, DMD, Ph.D., of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at ...

Tina Willits, now 53, thought she had just two years to live. Today, she is cancer-free — and she wants the world to know about the treatment that saved her.

For decades, the go-to treatments for cancer have been chemotherapy, radiation and surgery — but some experts are calling ...

As the founder and CEO of Immunocine Cancer Center, based in Cancún, Mexico, he has transformed his vision into reality with ...

CAN-2409 resulted in disease-free survival improvements for patients with high-risk, localized prostate cancer.

Dan G. Duda, DMD, PhD, of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital, is the corresponding author of a paper published in ...

The immunotherapy, CAN-2409, in combination with radiation therapy, helped 75.2% patients live without any sign of the cancer after 54 months of treatment, the company said on Wednesday.

Dan G. Duda, DMD, PhD, of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital ...

Checkpoint Therapeutics’ stock has seen a remarkable +60.26% year-to-date increase, far surpassing the S&P 500’s YTD performance of +26.86%. This highlights how well Checkpoint is positioning itself ...

FDA approved for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma that is not ...

Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General ... How would you summarize your study for a lay audience? Immunotherapy has revolutionized the ...